EI

259.5

-1.48%↓

SAN

84.4

-1.16%↓

MRK1

108.7

+0.83%↑

SHL.DE

47.28

0%↓

ARGX

603.4

+0.2%↑

EI

259.5

-1.48%↓

SAN

84.4

-1.16%↓

MRK1

108.7

+0.83%↑

SHL.DE

47.28

0%↓

ARGX

603.4

+0.2%↑

EI

259.5

-1.48%↓

SAN

84.4

-1.16%↓

MRK1

108.7

+0.83%↑

SHL.DE

47.28

0%↓

ARGX

603.4

+0.2%↑

EI

259.5

-1.48%↓

SAN

84.4

-1.16%↓

MRK1

108.7

+0.83%↑

SHL.DE

47.28

0%↓

ARGX

603.4

+0.2%↑

EI

259.5

-1.48%↓

SAN

84.4

-1.16%↓

MRK1

108.7

+0.83%↑

SHL.DE

47.28

0%↓

ARGX

603.4

+0.2%↑

Search

Laboratorios Farmaceuticos Rovi SA

Closed

SectorHealthcare

58.1 -0.34

Overview

Share price change

24h

Current

Min

57.75

Max

58.6

Key metrics

By Trading Economics

Income

3.9M

27M

Sales

4.8M

160M

P/E

Sector Avg

22.51

35.724

EPS

0.423

Dividend yield

1.62

Profit margin

16.767

Employees

2,188

EBITDA

4.2M

35M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+38.56% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

1.62%

3.09%

Next Earnings

6 Nov 2025

Market Stats

By TradingEconomics

Market Cap

161M

3B

Previous open

58.44

Previous close

58.1

News Sentiment

By Acuity

50%

50%

177 / 372 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Chart

Past performance is not a reliable indicator of future results.

Related News

28 Aug 2025, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28 Aug 2025, 23:48 UTC

Market Talk

Nikkei May Trade Rangebound; Data in Focus -- Market Talk

28 Aug 2025, 22:48 UTC

Market Talk

Eagers Automotive's Valuation Too High for Jefferies -- Market Talk

28 Aug 2025, 22:35 UTC

Earnings

Capricorn Metals Net Cash A$355.8 Million at June 30

28 Aug 2025, 22:35 UTC

Earnings

Capricorn Metals: Focused on Goal of Becoming Multi-mine, Mid-tier Gold Miner

28 Aug 2025, 22:35 UTC

Earnings

Capricorn Metals: Expects 'Another Strong Year' in FY26 for Karlawinda Gold Project

28 Aug 2025, 22:34 UTC

Earnings

Capricorn Metals FY Revenue A$505.9 Million, Up 41% On-Year

28 Aug 2025, 22:33 UTC

Earnings

Capricorn Metals FY Ebitda A$273.4 Million, Up 62% On-Year

28 Aug 2025, 22:33 UTC

Earnings

Capricorn Metals FY Profit Before Tax A$217.8 Million, Up 73% On-Year

28 Aug 2025, 22:32 UTC

Earnings

Capricorn Metals FY Net Profit A$150.3 Million, Up 72% On-Year

28 Aug 2025, 22:15 UTC

Earnings

Sayona Cash Balance A$72 Million at June 30

28 Aug 2025, 22:14 UTC

Earnings

Sayona FY Underlying Ebitda Loss A$67 Million

28 Aug 2025, 22:11 UTC

Earnings

Gold Road Resources Says Won't Pay an Interim Dividend

28 Aug 2025, 22:11 UTC

Earnings

Gold Road Resources 1H Ebitda A$201.8 Million, Roughly Doubles on Year

28 Aug 2025, 22:10 UTC

Earnings

Gold Road Resources 1H Revenue A$349.2 Million, Up 65% on Year

28 Aug 2025, 22:10 UTC

Earnings

Gold Road Resources 1H Net Profit A$107 Million, More Than Doubles

28 Aug 2025, 22:03 UTC

Earnings

Affirm Stock Rises 13% After Earnings. What Has Wall Street Excited. -- Barrons.com

28 Aug 2025, 21:54 UTC

Market Talk

Caterpillar Raises Its Forecasted Tariff Expense -- Market Talk

28 Aug 2025, 21:54 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

28 Aug 2025, 20:58 UTC

Earnings

Gap Stock Falls Despite Earnings Beat. Tariffs May Hurt. -- Barrons.com

28 Aug 2025, 20:58 UTC

Earnings

S&P 500, Dow Industrials Notch Records After GDP Revision -- WSJ

28 Aug 2025, 20:50 UTC

Earnings

Dell Beat Earnings Estimates. Why the Stock Is Down. -- Barrons.com

28 Aug 2025, 20:30 UTC

Earnings

Alibaba Earnings Are Coming. AI, Price Wars, and Tariffs Could Leave Their Mark. -- Barrons.com

28 Aug 2025, 20:28 UTC

Earnings

Dell Beat Earnings Estimates. Why the Stock Is Down. -- Barrons.com

28 Aug 2025, 20:22 UTC

Earnings

Nvidia Earnings Disappointed. GE Vernova and 5 More Industrial Stocks Get a Boost. -- Barrons.com

28 Aug 2025, 20:19 UTC

Earnings

Dell Beat Earnings Estimates. Why the Stock Is Down. -- Barrons.com

28 Aug 2025, 20:17 UTC

Earnings

Li Auto Stock Rises and Falls. How China's EV Price War Dented Earnings. -- Barrons.com

28 Aug 2025, 20:07 UTC

Earnings

IREN 4Q Rev $187.3M >IREN

28 Aug 2025, 19:23 UTC

Market Talk

Oil Futures Stage Late Turnaround -- Market Talk

28 Aug 2025, 19:11 UTC

Acquisitions, Mergers, Takeovers

Trump Fires Rail Regulator. Investors Are Taking Note. -- Barrons.com

Peer Comparison

Price change

Laboratorios Farmaceuticos Rovi SA Forecast

Price Target

By TipRanks

38.56% upside

12 Months Forecast

Average 80.85 EUR  38.56%

High 90 EUR

Low 71.7 EUR

Based on 2 Wall Street analysts offering 12 month price targets forLaboratorios Farmaceuticos Rovi SA - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

2

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

51.1 / N/ASupport & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

177 / 372 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.